Online inquiry

IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12490MR)

This product GTTS-WQ12490MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL20 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001385165.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50604
UniProt ID Q9NYY1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12490MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8567MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ114MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ4476MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ7054MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ6201MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ2266MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ8915MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ12005MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW